# Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

> **NCT00779922** · PHASE2 · COMPLETED · sponsor: **Poitiers University Hospital** · enrollment: 39 (actual)

## Conditions studied

- Multiple Myeloma
- Impaired Renal Function

## Interventions

- **DRUG:** lenalidomide

## Key facts

- **NCT ID:** NCT00779922
- **Lead sponsor:** Poitiers University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2012-09
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2016-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779922, "Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT00779922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*